You are here

Article Text

Article menu
Download PDFPDF
Adverse drug reactions
Type 2 diabetic female with vildagliptin associated eczematous eruption
  1. Ankur Guliani1,
  2. Tek Chand Yadav2,
  3. Krishna Jha3
  1. 1 Dermatology, Venereology and Leprology, Civil Hospital, Baddi, Himachal Pradesh, India
  2. 2 Internal Medicine, Bhagat Phool Singh Government Medical College for Women, Khanpur, Sonipat, Haryana, India
  3. 3 Dermatology, Post Graduate Institute of Medical Education and Research, Chandigarh, Chandigarh, India
  1. Correspondence to Ankur Guliani, Dermatology, Venereology and Leprology, Civil Hospital, Baddi 173205, Himachal Pradesh, India; gulianiankur502{at}gmail.com

http://dx.doi.org/10.1136/postgradmedj-2018-136378

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A 54-year-old woman was referred for dermatology consultation with a history of red, severely itchy lesions over the back and upper extremities. She complained of recent onset elevated lesions with dark coloured pigmentation over the same area. There was no personal or family history of atopy. On examination, there were few eczematous papules of variable sizes (maximum up to 1 cm diameter) distributed on the back and upper extremities. Additionally, she had mild lichenification (figure 1). Serum immunoglobulin E was 856 IU/mL and eosinophil count was 8.2%. She was prescribed oral antihistaminics and 0.05% clobetasol propionate cream for local application. However, the lesions were …

    View Full Text

    Footnotes

    • Contributors AG and TCY had full access to all the data used in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AG. Acquisition, analysis and interpretation of data: AG, TCY and KJ. Drafting of the manuscript: AG and KJ. Critical revision of the manuscript for important intellectual content: AG and TCY.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Obtained.

    • Provenance and peer review Not commissioned; externally peer reviewed.